Literature DB >> 11596117

Characterization of a 150 kDa accessory receptor for TGF-beta 1 on keratinocytes: direct evidence for a GPI anchor and ligand binding of the released form.

B Y Tam1, D Larouche, L Germain, N M Hooper, A Philip.   

Abstract

Transforming growth factor-beta (TGF-beta) is a key modulator of epidermal development and homeostasis, and has been shown to potently regulate keratinocyte migration and function during wound repair. There are three cloned TGF-beta receptors termed type I, type II, and type III that are found on most cell types. The types I and II are the signaling receptors, while the type III is believed to facilitate TGF-beta binding to the types I and II receptors. Recently, we reported that in addition to these receptors, human keratinocytes express a 150 kDa TGF-beta 1 binding protein (r150) which forms a heteromeric complex with the TGF-beta signaling receptors. This accessory receptor was described as glycosyl phosphatidylinositol-specific anchored based on its sensitivity to phosphatidylinositol phospholipase C (PIPLC). In the present study, we demonstrate that the GPI-anchor is contained in r150 itself and not on a tightly associated protein and that it binds TGF-beta 1 with an affinity similar to those of the types I and II TGF-beta signaling receptors. Furthermore, the PIPLC released (soluble) form of this protein is capable of binding TGF-beta 1 independently from the signaling receptors. In addition, we provide evidence that r150 is released from the cell surface by an endogenous phospholipase C. Our observation that r150 interacts with the TGF-beta signaling receptors, together with the finding that the soluble r150 binds TGF-beta 1 suggest that r150 in either its membrane anchored or soluble form may potentiate or antagonize TGF-beta signaling. Elucidating the mechanism by which r150 functions as an accessory molecule in TGF-beta signaling may be critical to understanding the molecular mechanisms underlying the regulation of TGF-beta action in keratinocytes. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596117     DOI: 10.1002/jcb.1074

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  Is hexamerin receptor a GPI-anchored protein in Achaea janata (Lepidoptera: Noctuidae)?

Authors:  Madhusudhan Budatha; Thuirei Jacob Ningshen; Aparna Dutta-Gupta
Journal:  J Biosci       Date:  2011-08       Impact factor: 1.826

Review 2.  Transforming Growth Factor Beta Signaling in Cutaneous Wound Healing: Lessons Learned from Animal Studies.

Authors:  Kenneth W Finnson; Praveen R Arany; Anie Philip
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-06       Impact factor: 4.730

3.  CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts.

Authors:  Xiao-Yong Man; Kenneth W Finnson; Murray Baron; Anie Philip
Journal:  Arthritis Res Ther       Date:  2012-06-13       Impact factor: 5.156

Review 4.  CD109 and squamous cell carcinoma.

Authors:  Ruixia Qi; Fengyun Dong; Qiang Liu; Yoshiki Murakumo; Ju Liu
Journal:  J Transl Med       Date:  2018-04-06       Impact factor: 5.531

5.  CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro.

Authors:  Shufeng Zhou; Sabrina Daniela da Silva; Peter M Siegel; Anie Philip
Journal:  Sci Rep       Date:  2019-11-06       Impact factor: 4.379

6.  CD109 Is a Critical Determinant of EGFR Expression and Signaling, and Tumorigenicity in Squamous Cell Carcinoma Cells.

Authors:  Shufeng Zhou; Amani Hassan; Tenzin Kungyal; Sebastien Tabariès; José Luis Ramírez García Luna; Peter M Siegel; Anie Philip
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

Review 7.  Dynamics of Transforming Growth Factor Beta Signaling in Wound Healing and Scarring.

Authors:  Kenneth W Finnson; Sarah McLean; Gianni M Di Guglielmo; Anie Philip
Journal:  Adv Wound Care (New Rochelle)       Date:  2013-06       Impact factor: 4.730

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.